ADMA Biologics, Inc. (ADMA) Q3 2017 Earnings Results

ADMA BioLogics Misses on EPS, Stock Up 1.59%

ADMA BioLogics reported a loss per share of $0.59, but the stock rose by 1.59% following the earnings call. Investors may have reacted positively to management's comments about future growth prospects and operational improvements, despite the lack of specific revenue figures or guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.59	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about future developments. They emphasized their focus on improving operational efficiencies.

Management highlighted ongoing efforts to enhance product offerings.

They reiterated their commitment to long-term growth despite current challenges.

ADMA BioLogics Misses on EPS, Stock Up 1.59%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA BioLogics Misses on EPS, Stock Up 1.59%

Key numbers

Management commentary